What You Need to Know
The financial results for the third quarter of 2023 revealed net sales of $7.6 million, surpassing sales expectations.
Seres provided updates on its investigational therapeutic, SER-155, designed to prevent enteric-derived infections and reduce the incidence of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Data from the ECOSPOR IV study, a multicenter, randomized, placebo-controlled, open-label study, highlighted the efficacy of SER-109 in preventing recurrent CDI.
SER-155 Update
In its earnings report, the company said its SER-155 phase 1b placebo-controlled cohort 2 data readout is anticipated in mid-2024. SER-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune tolerance responses to reduce the incidence of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Gastrointestinal (GI) microbiome data from the first 100 days post HSCT in cohort 1 of the SER-155 phase 1b open-label study showed the successful engraftment of SER-155 bacterial strains and a substantial reduction in the cumulative incidence of pathogen domination, a biomarker associated with the risk of serious enteric infections and bloodstream infections, as well as GvHD. The tolerability profile observed was favorable, with no serious adverse events attributed to SER-155 administration.
What the Vowst Data Showed
In earlier reporting by Contagion, Seres shared data from its clinical studies. The ECOSPOR IV (NCT03183141) multicenter, randomized, placebo-controlled, open-label study included 2 cohorts of adults with rCDI. Enrolled patients had a clinical profile consistent with those frequently evaluated and treated in clinical practice.
The participants treated with SER-109 had a recurrence rate of 8.7% at 8 weeks, indicating a 91.3% sustained clinical response. At 24 weeks, 13.7% of all subjects treated with SER-109 had a CDI recurrence.
SER-109 was well-tolerated through 24 weeks. The safety profile observed in ECOSPOR IV was consistent with that of its preceding placebo-controlled study, ECOSPOR III. Together, these 2 trials complete the SER-109 phase 3 development program.
Seres is also participating in the Peggy Lillis Foundation’s 2023 State of C diff Virtual Town Hall, which is happening today at 6pm EST. This is a digital event open to the public. To learn more about the event go here.
Reference
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including Vowst Net Sales of $7.6 Million. Seres Press release. November 2, 2023. https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-third-quarter-2023-financial-results